Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,048.00-5.32%ETH$2,240.30-7.39%GOLD$4,077.50-0.88%OIL$91.03+0.56%
Smart Investors Daily
SID Premium
CO

NASDAQ · COGT

Cogent Biosciences, Inc. Common Stock

Healthcare · Biotechnology

$29.58

Down-$1.91 (-6.07%)

Updated Nov 6, 2026, 10:38 AM

SID Score

5.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
5.7B
P/E ratio
-16.13
Dividend yield
0.00%
52-week range
$13.78 – $43.73
Volume
2.73M
Avg. volume
3.12M

Price performance · COGT

COGT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 5, 2026

COGT closed at $29.58 after 21 trading sessions, down 1.66% for the selected period.

Last close
$29.58
Period change
-1.66%
Period low
$28.09
Period high
$32.23
Daily close
View OHLC price history
COGT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 5, 2026$31.34$31.41$29.155$29.582.73M
Nov 4, 2026$32.03$32.03$29.935$31.492.23M
Nov 3, 2026$30.08$31.27$30.06$31.061.88M
Nov 2, 2026$31.31$31.475$29.69$29.732M
Oct 30, 2026$31.75$32.335$30.645$31.022.5M
Oct 29, 2026$32.86$32.86$31.68$31.961.52M
Oct 28, 2026$31.77$32.68$31.68$32.231.75M
Oct 27, 2026$31.10$32.22$30.72$32.011.84M
Oct 26, 2026$31.41$31.545$30.52$30.912.21M
Oct 23, 2026$30.94$31.2651$30.33$31.211.77M
Oct 22, 2026$31.07$31.91$30.86$31.311.18M
Oct 21, 2026$31.26$31.94$31.20$31.432.1M
Oct 20, 2026$30.235$31.50$30.03$31.242.31M
Oct 19, 2026$29.66$30.23$29.51$30.012.54M
Oct 16, 2026$29.47$29.98$28.77$29.522.78M
Oct 15, 2026$28.33$29.78$28.33$29.513.04M
Oct 14, 2026$27.93$29.05$27.735$28.152.3M
Oct 13, 2026$29.46$29.46$27.85$28.093M
Oct 12, 2026$30.81$31.07$29.63$29.781.86M
Oct 9, 2026$29.98$31.03$29.90$31.002.52M
Oct 8, 2026$29.71$30.66$28.69$30.083.64M

Latest COGT news

The latest Smart Investors Daily articles mentioning COGT.

Stock researchCompany · Overview

COGT research

Overview

Company profile and research snapshot.

Company profile

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.20
Implied upside
—
Analysts
—
COGT recent ratings
DateFirmRatingTarget
Sep 16, 2026WedbushOutperform—
Sep 15, 2026HC Wainwright & Co.Buy—
Aug 17, 2026Piper SandlerOverweight—
Aug 12, 2026GuggenheimBuy—
May 29, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, 2026 at 7:30 a.m. ET. A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/ev

Yahoo · Oct 20, 2026

Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?

Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November 30 target for a combination treatment in gastrointestinal stromal tumors, rather than on the earnings of […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By